PALLA, ROBERTA
PALLA, ROBERTA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Congenital fibrinogen disorders: a retrospective clinical and genetic analysis of the Prospective Rare Bleeding Disorders Database
2024 S. Mohsenian, R. Palla, M. Menegatti, A. Cairo, A. Lecchi, A. Casini, M. Neerman-Arbez, R. Asselta, S. Scardo, S.M. Siboni, J. Blatny, O. Zapletal, J. Schved, M. Giansily-Blaizot, S. Halimeh, M.A. Daoud, H. Platokouki, H. Pergantou, R.E.G. Schutgens, M. Van Haaften-Spoor, P. Brons, B. Laros-van Gorkom, E. Van Pinxten, M. Borhany, N. Fatima, D. Mikovic, M. Saracevic, G.N. Özdemir, Y. Ay, M. Makris, C. Lockley, A. Mumford, A. Harvey, S. Austin, A. Shapiro, A. Williamson, C. Mcguinn, I. Goldberg, P. De Moerloose, F. Peyvandi
Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort
2024 S. Hassan, G. Baselli, L. Mollica, R.L. Rossi, H. Chand, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, M. Karimi, R. Palla, F.R. Rosendaal, F. Peyvandi
Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis
2024 S. Arcudi, R. Gualtierotti, E. Scalambrino, M. Clerici, S. Hassan, V. Begnozzi, E.A. Boccalandro, C. Novembrino, C. Valsecchi, R. Palla, F. Peyvandi
Diagnostic utility of bleeding assessment tools in congenital fibrinogen deficiencies
2023 S. Mohsenian, O. Seidizadeh, R. Palla, M. Jazebi, A. Azarkeivan, S. Moazezi, M.R. Baghaipour, M. Menegatti, F. Peyvandi
Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency
2022 C. Pier Giorgio, Z. Ezio, P. Samantha, P. Federico, L. Banov, C. Biasioli, P. Di Gregorio, A. Ferretti, A. Claudio Molinari, L. Dora Notarangelo, R. Palla, F. Payvandi, M. Pizzuti, B. Pollio, G. Sottilotta, S. Maria Siboni
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
2021 S. Hassan, R. Palla, C. Valsecchi, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, M. Karimi, S.C. Gouw, P.M. Mannucci, F.R. Rosendaal, F. Peyvandi
Hemostatic alterations in COVID-19
2021 F. Peyvandi, A. Artoni, C. Novembrino, S. Aliberti, M. Panigada, M. Boscarino, R. Gualtierotti, F. Rossi, R. Palla, I. Martinelli, G. Grasselli, F. Blasi, A. Tripodi
No changes of parameters nor coagulation activation in healthy subjects vaccinated for {SARS}-Cov-2
2021 F. Payvandi, E. Scalambrino, M. Clerici, A. Lecchi, N. Revelli, R. Palla, R. Gualtierotti, D. Prati, A. Tripodi
Lombardy network for the study and treatment of patients undergoing apheresis
2020 I. Mancini, P. Agosti, M. Boscarino, B. Ferrari, A. Artoni, R. Palla, L. Barcella, A. Falanga, F. Peyvandi
Lombardy Network for the Study and Treatment of Patients Undergoing Apheresis
2020 I. Mancini, P. Agosti, M. Boscarino, B. Ferrari, A. Artoni, R. Palla, L. Barcella, A. Falanga, F. Peyvandi
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A
2020 F. Peyvandi, S. Miri, P. Bucciarelli, C. Valsecchi, L. Schiavone, M. Boscarino, R. Palla, P.M. Mannucci, F.R. Rosendaal
An international registry of patients with plasminogen deficiency (HISTORY)
2020 A.D. Shapiro, M. Menegatti, R. Palla, M. Boscarino, C. Roberson, P. Lanzi, J. Bowen, C. Nakar, I.A. Janson, F. Peyvandi
Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A
2019 Y. Repessé, C. Costa, R. Palla, E. Farrokhi Moshai, A. Borel-Derlon, R. D'Oiron, C. Rothschild, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, J. Oldenburg, A. Pavlova, F.R. Rosendaal, F. Peyvandi, S.V. Kaveri, S. Lacroix-Desmazes
Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopenic Purpura: Fourteen Years of the Milan TTP Registry
2019 I. Mancini, S. Pontiggia, R. Palla, A. Artoni, C. Valsecchi, B. Ferrari, D. Mikovic, F. Payvandi
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis"
2019 A. Messori, F. Peyvandi, S. Trippoli, R. Palla, F.R. Rosendaal, P.M. Mannucci
Risk factors for inhibitor development in severe hemophilia A
2018 I. Garagiola, R. Palla, F. Peyvandi
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
2018 A. Messori, F. Peyvandi, S. Trippoli, R. Palla, F.R. Rosendaal, P.M. Mannucci
Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey
2018 F. Payvandi, R. Palla, C. Franchi, A. Nobili, F.R. Rosendaal, P.M. Mannucci
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis
2018 F. Peyvandi, A. Cannavò, I. Garagiola, R. Palla, P.M. Mannucci, F.R. Rosendaal, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D.M. Nayak, E. Santagostino, M. Elisa Mancuso, A.C. Sandoval Gonzalez, J.N. Mahlangu, S. Bonanad Boix, M. Cerqueira, N.P. Ewing, C. Male, T. Owaidah, V. Soto Arellano, N.L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakl, M.J. Manco-Johnson, M. Martinez, E. Marzouka, M.G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B.M. Wicklund, B. Zulfikar
Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A : A SIPPET analysis
2017 F.R. Rosendaal, R. Palla, I. Garagiola, P.M. Mannucci, F. Peyvandi